Stephens Investment Management Group LLC Exelixis, Inc. Transaction History

Stephens Investment Management Group LLC

$7.08 Billion
Q3 2024

A detailed history of Stephens Investment Management Group LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Stephens Investment Management Group LLC holds 3,806,564 shares of EXEL stock, worth $128 Million. This represents 1.4% of its overall portfolio holdings.

Number of Shares

3,806,564

Previous 3,880,507 1.91%

Holding current value

$128 Million

Previous $87.2 Million 13.29%

% of portfolio

1.4%

Previous 1.26%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$21.96 - $27.6 $1.62 Million - $2.04 Million	-73,943 Reduced 1.91%	3,806,564 $98.8 Million
Q2 2024 Aug 06, 2024	SELL	$20.34 - $23.73 $673,681 - $785,961	-33,121 Reduced 0.85%	3,880,507 $87.2 Million
Q1 2024 May 14, 2024	SELL	$20.17 - $23.93 $3.89 Million - $4.62 Million	-193,036 Reduced 4.7%	3,913,628 $92.9 Million
Q4 2023 Feb 13, 2024	SELL	$19.25 - $24.13 $1.71 Million - $2.15 Million	-88,924 Reduced 2.12%	4,106,664 $98.5 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $604,044 - $721,426	31,725 Added 0.76%	4,195,588 $91.7 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $1.63 Million - $1.83 Million	89,543 Added 2.2%	4,163,863 $79.6 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $441,241 - $525,428	27,070 Added 0.67%	4,074,320 $79.1 Million
Q4 2022 Jan 26, 2023	SELL	$14.96 - $17.39 $388,376 - $451,461	-25,961 Reduced 0.64%	4,047,250 $63.4 Million
Q3 2022 Nov 07, 2022	BUY	$15.68 - $22.27 $376,351 - $534,524	24,002 Added 0.59%	4,073,211 $63.9 Million
Q2 2022 Aug 03, 2022	SELL	$17.44 - $23.16 $84,897 - $112,742	-4,868 Reduced 0.12%	4,049,209 $84.3 Million
Q1 2022 May 04, 2022	BUY	$17.03 - $22.67 $989,357 - $1.32 Million	58,095 Added 1.45%	4,054,077 $91.9 Million
Q4 2021 Feb 15, 2022	BUY	$15.84 - $21.88 $8.93 Million - $12.3 Million	563,835 Added 16.43%	3,995,982 $73 Million
Q3 2021 Oct 27, 2021	BUY	$16.3 - $21.14 $8.3 Million - $10.8 Million	508,967 Added 17.41%	3,432,147 $72.6 Million
Q2 2021 Aug 09, 2021	BUY	$17.95 - $25.56 $10 Million - $14.3 Million	558,482 Added 23.62%	2,923,180 $53.3 Million
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $19.6 Million - $24.1 Million	954,852 Added 67.73%	2,364,698 $53.4 Million
Q4 2020 Feb 10, 2021	SELL	$18.39 - $24.8 $647,107 - $872,662	-35,188 Reduced 2.44%	1,409,846 $28.3 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $900,963 - $1.17 Million	-43,588 Reduced 2.93%	1,445,034 $35.3 Million
Q2 2020 Aug 24, 2020	BUY	$16.46 - $27.42 $997,492 - $1.66 Million	60,601 Added 4.24%	1,488,622 $35.3 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $8.05 Million - $12.1 Million	556,747 Added 63.9%	1,428,021 $24.6 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $848 - $1,057	-56 Reduced 0.01%	871,274 $15.4 Million
Q3 2019 Oct 18, 2019	BUY	$17.68 - $22.65 $402,379 - $515,491	22,759 Added 2.68%	871,330 $15.4 Million
Q2 2019 Aug 01, 2019	BUY	$18.93 - $24.75 $129,235 - $168,968	6,827 Added 0.81%	848,571 $18.1 Million
Q1 2019 May 03, 2019	BUY	$19.6 - $24.76 $133,142 - $168,194	6,793 Added 0.81%	841,744 $20 Million
Q4 2018 Feb 11, 2019	BUY	$13.65 - $21.8 $1.92 Million - $3.07 Million	140,709 Added 20.27%	834,951 $16.4 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $31,993 - $45,158	2,016 Added 0.29%	694,242 $12.3 Million
Q2 2018 Aug 10, 2018	BUY	$18.56 - $22.45 $4.32 Million - $5.23 Million	232,761 Added 50.66%	692,226 $14.7 Million
Q1 2018 May 04, 2018	BUY	$22.15 - $31.89 $17,299 - $24,906	781 Added 0.17%	459,465 $10.2 Million
Q4 2017 Feb 05, 2018	BUY	$24.23 - $30.93 $11.1 Million - $14.2 Million	458,684	458,684 $13.9 Million

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Investment Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Investment Management Group LLC with notifications on news.

Account

Stephens Investment Management Group LLC Exelixis, Inc. Transaction History